First‐in‐human Phase I Study of E7090, a Novel Selective FGFR Inhibitor, in Patients With Advanced Solid Tumors
Cancer Science - United States
doi 10.1111/cas.14265
Full Text
Open PDFAbstract
Available in full text
Date
February 1, 2020
Authors
Publisher
Wiley